INSULIN GLARGINE | B210605 | MYLAN PHARMS INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Jun. 11, 2032 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12318584(device) · relevance 75/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 181 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
SANOFI-AVENTIS U.S. LLC et al v. MYLAN N.V. et al 18 patentsinsulin glargine [rDNA origin] | D.N.J. | 2017-10-24 | Terminated 2020-11-02 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.